65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014 Reported by Jules Levin AASLD 2014 Nov 7-11 Boston Fred Lahser1, Karin Bystol1, Stephanie Curry1, Patricia McMonagle1, Rong Liu1, Ellen ... National AIDS Treatment Advocacy Project, 1 week ago
C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8472) + Sofosbuvir in Treatment-Nave Patients with Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6 or 8 Weeks (Interim Results) - National AIDS Treatment Advocacy Project, 2 weeks ago
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
The Lancet, Early Online Publication, 11 November 2014 Eric Lawitz, Edward Gane, Brian Pearlman, Edward Tam, Wayne Ghesquiere, Dominique Guyader, Laurent Alric, Jean-Pierre Bronowicki, Laura Lester, William Sievert, Reem Ghalib, Luis Balart, ...National AIDS Treatment Advocacy Project, 1 week ago Excellent Results for 12 and 18 Weeks of Merck's Dual Hep C Regimen AIDSmeds, 1 week ago Merck (MRK) Updates on MK-5172/MK-8742 Phase 2 Wall Street Business Network, 1 week ago Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hcv Gt1 Infected Patients with cirrhosis or previous null reSPonse: FINAL RESULTS OF the C-WORTHY Study (PARTS A AND B) National AIDS Treatment Advocacy Project, 1 week ago
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir MK-5172/MK-8742 at the 65th...
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir MK-5172/MK-8742 at the 65th American Association for the Study of Liver Diseases Annual Meeting By a News Reporter-Staff News ...4 Traders, 1 month ago Merck Posts Data For Triple-Drug HCV Regimen Bioresearch Online, 1 week ago MERCK : Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients 4 Traders, 1 week ago Merck & Co.???s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir In Combination With A Nucleotide Inhibitor (C-SWIFT Study) Presented At The Liver Meeting?? BioSpace, 2 weeks ago
Heyneman D. Immunology of leishmaniasis. Bull. World Health Organ. 44(4), 499514 (1971). Antoine JC, Prina E, Lang T et al. The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Trends ...Medscape, 3 days ago
Gastroenterology Published: Nov 16, 2014 BOSTON -- A new study suggests that some subgroups of patients with hepatitis C (HCV) infection can achieve sustained virologic responses (SVR) in as short as 4 weeks using an aggressive, investigational ...MedPage Today, 1 week ago Shorter Treatment Shows Promise With Investigative HCV Agents MedPage Today, 1 week ago
Meeting Coverage Published: Nov 13, 2014 This report is part of a 12-month Clinical Context series. ByEd Susman , Contributing Writer, MedPage Today BOSTON -- An investigational combination treatment appears to allow difficult-to-treat ...MedPage Today, 1 week ago
BOSTON — A number of patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, and patients co-infected with HIV and HCV, achieved sustained virologic response at 12 weeks when treated grazoprevir and elbasvir, with or ...Orthopedics Today, 1 week ago C-WORTHy: Grazoprevir/elbasvir achieved SVR12 in more than 90% of patients Orthopedics Today, 1 week ago
Merck (NYSE:MRK) recently released some data from clinical trials of a triple-pill regimen for the treatment of treatment-naive group of cirrhotic patients. Cirrhotic patients refer to individuals with significant liver scarring, or the replacement ...Trefis, 1 week ago
US pharma giant Merck & Co (NYSE: MRK) has admitted that interim data from its triple-therapy regimen in hepatitis C has shown sub-optimal efficacy. The data from the C-SWIFT study explored the potential of a candidate triple-therapy regimen ...Pharma Letter, 1 week ago
Merck & Co. Inc. ( MRK ) presented interim data from a proof-of-concept (C-SWIFT) study on its fixed-dose combination regimen grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A) plus Gilead's ( GILD ) Sovaldi (sofosbuvir a nucleotide inhibitor) for ...Yahoo! Finance, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!